Elektrofi Receives Contract Under the Defense Health Agency SBIR/STTR Program to Advance Antibody Delivery Formulations for the Treatment of Covid-19 and Future Pandemics
Elektrofis platform formulation technology aims to provide an alternative to current delivery methods for antibody treatments, which require intravenous administration in a healthcare setting.
- Elektrofis platform formulation technology aims to provide an alternative to current delivery methods for antibody treatments, which require intravenous administration in a healthcare setting.
- Our platform technology can re-engineer these formulations for easier delivery and distribution, opening up the possibility for non-critical patients to receive a ready-to-use therapeutic easily, at home.
- Elektrofi may be eligible to extend this funding through an enhancement program requiring matched funds from an outside funding source.
- For this contract, Elektrofi will evaluate candidate industry partners with promising antibody or antibody cocktail therapies for the treatment of COVID-19.